




*Institutional Review Board/Privacy Board*

**TO:** Vincent Miller, MD  
Department of Medicine

**FROM:** Roger S. Wilson, MD  
Chairman, IRB/Privacy Board 

**DATE:** June 1<sup>st</sup>, 2004

**RE:** Request for Waiver of Authorization, WA0199-04

---

Your request for a Waiver of Authorization entitled "Molecular Determinants of Sensitivity and Resistance to Gefitinib" was reviewed by the Privacy Board and was ***approved.***

The Waiver of Authorization is approved only for the reasons set out in your request. The approval number is WA0199-04. Please remember that you, the Principal Investigator, are responsible for tracking the disclosure of PHI under this waiver. Before you disclose any information outside the institution, the data set needs to be reviewed and approved by the Privacy Office or its representatives. Please E-mail the data set to [hipaares@mskcc.org](mailto:hipaares@mskcc.org). If you have any questions, please call the HIPAA Research Help Line (646-735-8048). In addition, if you would like to review the same PHI for a different research question, another waiver of authorization must be submitted to the Privacy Board.



*Institutional Review Board/Privacy Board*

**TO:** Dr. V. A. Miller

**FROM:** Dr. Roger S. Wilson  
*Roger S. Wilson*  
Chairman, Institutional Review Board/Privacy Board

**DATE:** February 25, 2004

**RE:** Protocol and Consent Form Amendments for Protocol #92-055A(12)

Your protocol and consent form amendments for Protocol #92-055A(12) entitled "Preclinical Studies of Blood, Urine, Bone Marrow, and Tissues Collected from Patients with Lung Cancer and Mesothelioma", as outlined in your attached memo, were reviewed at the February 24, 2004 Institutional Review Board/Privacy Board meeting and were approved.


RSW: ac  
Enclosure

*Memorial Sloan-Kettering Cancer Center  
1275 York Avenue, New York, New York 10021  
Telephone 212 639 7592*

*NCI-designated Comprehensive Cancer Center*



*Institutional Review Board/Privacy Board*

**TO:** Dr. Vincent Miller  
**FROM:** Dr. Roger S. Wilson   
Chairman, Institutional Review Board/Privacy Board  
**DATE:** July 14, 2004  
**RE:** Protocol and Consent Form Amendments for Protocol # 02-010A(9)

Your protocol and consent form amendments for Protocol # 02-010A(9) entitled "Multicenter Phase II Trial of OSI-774 (Erlotinib, Tarceva<sup>TM</sup>) in Patients with Advanced Bronchioloalveolar Cell Lung Cancer", as outlined in your attached memo, were reviewed at the July 13, 2004 Institutional Review Board meeting and were approved.

RSW:ch  
Enclosure

*Memorial Sloan-Kettering Cancer Center  
1275 York Avenue, New York, New York 10021  
Telephone 212 639 7592*

*NCI-designated Comprehensive Cancer Center*